Revolution Medicines’ Clinical Trial Program Is Evaluating Investigational Treatments for RAS-Mutant Cancers
Revolution Medicines’ RAS(ON) Inhibitor Clinical Trials Program
Daraxonrasib (RMC-6236) | RAS(ON) multi-selective inhibitor
Therapeutic Area
Clinical Studies
Phase
Key Eligibility Criteriaa
+Monotherapy Studies
PDAC
3
- Confirmed metastatic disease
- Documented RAS mutation status, either mutant or wild-type
- No prior therapy with direct RAS‑targeted therapy
- No history of known central nervous system metastatic disease
NSCLC
3
- Confirmed locally advanced or metastatic disease
- Documented RAS mutation status
- No prior therapy with direct RAS‑targeted therapy or docetaxel
- No untreated central nervous system (CNS) metastases
Advanced solid tumors
1/1b
- Confirmed advanced disease
- Documented specific KRAS G12 mutations
- Received prior standard therapy
- Adequate organ function
- No active brain metastases
Combination Studies
NSCLC
1b/2
- Advanced or metastatic KRAS G12C-mutant solid tumor not amenable to curative therapyb
- Advanced or metastatic RAS‑mutant NSCLCb
- Advanced or metastatic RAS G12D-mutant NSCLCb
- Adequate organ function
- Received appropriate prior standard therapy
- No primary central nervous system (CNS) tumors
Advanced solid tumors
1/1b
- Locally advanced or metastatic disease that is KRAS G12D-mutant
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy)
- No primary central nervous system (CNS) tumors
Advanced solid tumors
1/2
- Documented pancreatic carcinoma
- Poorly differentiated pancreatic carcinoma with metastatic disease
- RAS‑mutant colorectal adenocarcinoma with advanced/metastatic diseaseb
- Presence of RAS G12D mutationb
- No primary central nervous system (CNS) tumors or impaired gastrointestinal function
Advanced solid tumors
1b
- Advanced or metastatic disease that is KRAS G12C-mutant and not amenable to curative therapy
- Adequate organ function
- No active brain metastases
Zoldonrasib (RMC-9805) | RAS(ON) G12D-selective inhibitor
Therapeutic Area
Clinical Studies
Phase
Key Eligibility Criteriaa
+Monotherapy Studies
Advanced solid tumors
1/1b
- Locally advanced or metastatic disease that is KRAS G12D-mutant
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy)
- No primary central nervous system (CNS) tumors
Combination Studies
NSCLC
1b/2
- Advanced or metastatic KRAS G12C-mutant solid tumor not amenable to curative therapyb
- Advanced or metastatic RAS‑mutant NSCLCb
- Advanced or metastatic RAS G12D-mutant NSCLCb
- Adequate organ function
- Received appropriate prior standard therapy
- No primary central nervous system (CNS) tumors
Advanced solid tumors
1/1b
- Locally advanced or metastatic disease that is KRAS G12D-mutant
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy)
- No primary central nervous system (CNS) tumors
Advanced solid tumors
1/2
- Documented pancreatic carcinoma
- Poorly differentiated pancreatic carcinoma with metastatic disease
- RAS‑mutant colorectal adenocarcinoma with advanced/metastatic diseaseb
- Presence of RAS G12D mutationb
- No primary central nervous system (CNS) tumors or impaired gastrointestinal function
Elironrasib (RMC-6291) | RAS(ON) G12C-selective inhibitor
Therapeutic Area
Clinical Studies
Phase
Key Eligibility Criteriaa
+Monotherapy Studies
Advanced solid tumors
1/1b
- Confirmed locally advanced or metastatic solid tumor malignancy
- Documented KRAS G12C mutation
- No prior therapy with a KRAS G12C (ON) inhibitor
- No primary central nervous system (CNS) tumors
Combination Studies
NSCLC
1b/2
- Advanced or metastatic KRAS G12C-mutant solid tumor not amenable to curative therapyb
- Advanced or metastatic RAS‑mutant NSCLCb
- Advanced or metastatic RAS G12D-mutant NSCLCb
- Adequate organ function
- Received appropriate prior standard therapy
- No primary central nervous system (CNS) tumors
Advanced solid tumors
1b
- Advanced or metastatic disease that is KRAS G12C-mutant and not amenable to curative therapy
- Adequate organ function
- No active brain metastases
aThis is not a complete list of eligibility criteria; for more information, please go to ClinicalTrials.gov. bThese criteria are for specific subprotocols within the clinical trial. cThere are monotherapy and combination therapy arms for zoldonrasib (RMC-9805) in each of these studies. Refer to the ClinicalTrials.gov record for more information.
